Research · Meta-analysis
Alpha-lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials
What it found
Reduced neuropathic symptoms (pooled Total Symptom Score change −2.26); the effect was largest and most clinically relevant for short-term IV 600 mg/day, with oral dosing less certain.
- Design
- Meta-analysis
- Year
- 2012
- Sample size
- 653
- Population
- patients with diabetes and symptomatic peripheral neuropathy (4 RCTs)
- Intervention
- alpha-lipoic acid, oral (>600 mg/day) or intravenous (600 mg/day for ~3 weeks)
- Outcome
- Total Symptom Score (neuropathic pain, burning, numbness)
- Journal
- International Journal of Endocrinology
Citation last checked 2026-06-21.